Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides

For buccal administration of proteins and peptides with therapeutic interest, formulations must be mucoadhesive and present one or more permeability enhancers as nanoparticles to cross the mucus layer (A) and permeate the epithelia (B) to finally reach the blood stream (C). A portion of carried prot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Peptides (New York, N.Y. : 1980) N.Y. : 1980), 2018-03, Vol.101, p.112-123
Hauptverfasser: Batista, Patrícia, Castro, Pedro M., Madureira, Ana Raquel, Sarmento, Bruno, Pintado, Manuela
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 123
container_issue
container_start_page 112
container_title Peptides (New York, N.Y. : 1980)
container_volume 101
creator Batista, Patrícia
Castro, Pedro M.
Madureira, Ana Raquel
Sarmento, Bruno
Pintado, Manuela
description For buccal administration of proteins and peptides with therapeutic interest, formulations must be mucoadhesive and present one or more permeability enhancers as nanoparticles to cross the mucus layer (A) and permeate the epithelia (B) to finally reach the blood stream (C). A portion of carried proteins/peptides will be swallowed. Nanoparticles will protect the integrity of carried proteins and peptides while in contact with acidic pH and proteases secreted in the stomach (D), allowing the carried molecules to permeate the intestinal epithelia (E) to reach the bloodstream. [Display omitted] •Oral delivery of proteins and peptides with therapeutic interest can be achieved.•Buccal delivery of therapeutic proteins and peptides represents an attractive, unexplored type of delivery rout.•Nanoparticles represent useful tools to highly increase the effectiveness of proteins and peptides administered per os.•Size, zeta potential, mucoadhesion or physicochemical composition must be tailored according to carried protein/peptide.•Nanoparticle functionalization and/or inclusion of nanocarriers within mucoadhesive delivery systems can induce an overall increase of bioavailability of carried proteins and peptides. Bioactive proteins and peptides have been used with either prophylactic or therapeutic purposes, presenting inherent advantages as high specificity and biocompatibility. Nanocarriers play an important role in the stabilization of proteins and peptides, offering enhanced buccal permeation and protection while crossing the gastrointestinal tract. Moreover, preparation of nanoparticles as oral delivery systems for proteins/peptides may include tailored formulation along with functionalization aiming bioavailability enhancement of carried proteins or peptides. Oral delivery systems, namely buccal delivery systems, represent an interesting alternative route to parenteric delivery systems to carry proteins and peptides, resulting in higher comfort of administration and, therefore, compliance to treatment. This paper outlines an extensive overview of the existing publications on proteins/peptides oral nanocarriers delivery systems, with special focus on buccal route. Manufacturing aspects of most commonly used nanoparticles for oral delivery (e.g. polymeric nanoparticles using synthetic or natural polymers and lipid nanoparticles) advantages and limitations and potential applications of nanoparticles as proteins/peptides delivery systems will also be thoroughly addre
doi_str_mv 10.1016/j.peptides.2018.01.002
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2067254211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196978118300020</els_id><sourcerecordid>2067254211</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-deeee5aa05eec8cb0bde53598cdc5173299ba4e21f487e81735afbdc122462a13</originalsourceid><addsrcrecordid>eNqFkU2PFCEQhonRuOPqX9hw8OCl24KGbrhpNn4lm5gYPRMaql0mPU0LzCT776WdHa_LBQqeqnqpl5AbBi0D1r_ftyuuJXjMLQemWmAtAH9GdkwNXSNZr5-THTDdN3pQ7Iq8ynkPAEJo9ZJccd1xrYdhR9wPdLgUGpYcft-XXA-03CM9ZqRxootdorMpBUyZTjH9e4vJztTjHE6YHjZqDNG6UkO6pliw1qJ28fSi8DV5Mdk545vH_Zr8-vzp5-3X5u77l2-3H-8aJzoojce6pLUgEZ1yI4weZSe1ct5JNmyKRyuQs0moAVW9kXYavWOci55b1l2Td-e6VcWfI-ZiDiE7nGe7YDxmw6EfuBScPY0yrbRUgoOoaH9GXYo5J5zMmsLBpgfDwGxemL25_NRsXhhgpnpRE28eexzHA_r_aZfhV-DtGUjO2tUkPIVcbG0OAmppYbgcYMM-nDGssztVJ0x2AReHPiR0xfgYnpLyFwLXqw4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1989584204</pqid></control><display><type>article</type><title>Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Batista, Patrícia ; Castro, Pedro M. ; Madureira, Ana Raquel ; Sarmento, Bruno ; Pintado, Manuela</creator><creatorcontrib>Batista, Patrícia ; Castro, Pedro M. ; Madureira, Ana Raquel ; Sarmento, Bruno ; Pintado, Manuela</creatorcontrib><description>For buccal administration of proteins and peptides with therapeutic interest, formulations must be mucoadhesive and present one or more permeability enhancers as nanoparticles to cross the mucus layer (A) and permeate the epithelia (B) to finally reach the blood stream (C). A portion of carried proteins/peptides will be swallowed. Nanoparticles will protect the integrity of carried proteins and peptides while in contact with acidic pH and proteases secreted in the stomach (D), allowing the carried molecules to permeate the intestinal epithelia (E) to reach the bloodstream. [Display omitted] •Oral delivery of proteins and peptides with therapeutic interest can be achieved.•Buccal delivery of therapeutic proteins and peptides represents an attractive, unexplored type of delivery rout.•Nanoparticles represent useful tools to highly increase the effectiveness of proteins and peptides administered per os.•Size, zeta potential, mucoadhesion or physicochemical composition must be tailored according to carried protein/peptide.•Nanoparticle functionalization and/or inclusion of nanocarriers within mucoadhesive delivery systems can induce an overall increase of bioavailability of carried proteins and peptides. Bioactive proteins and peptides have been used with either prophylactic or therapeutic purposes, presenting inherent advantages as high specificity and biocompatibility. Nanocarriers play an important role in the stabilization of proteins and peptides, offering enhanced buccal permeation and protection while crossing the gastrointestinal tract. Moreover, preparation of nanoparticles as oral delivery systems for proteins/peptides may include tailored formulation along with functionalization aiming bioavailability enhancement of carried proteins or peptides. Oral delivery systems, namely buccal delivery systems, represent an interesting alternative route to parenteric delivery systems to carry proteins and peptides, resulting in higher comfort of administration and, therefore, compliance to treatment. This paper outlines an extensive overview of the existing publications on proteins/peptides oral nanocarriers delivery systems, with special focus on buccal route. Manufacturing aspects of most commonly used nanoparticles for oral delivery (e.g. polymeric nanoparticles using synthetic or natural polymers and lipid nanoparticles) advantages and limitations and potential applications of nanoparticles as proteins/peptides delivery systems will also be thoroughly addressed.</description><identifier>ISSN: 0196-9781</identifier><identifier>EISSN: 1873-5169</identifier><identifier>DOI: 10.1016/j.peptides.2018.01.002</identifier><identifier>PMID: 29329977</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Oral ; Bioactive protein/peptides ; bioavailability ; biocompatibility ; Buccal delivery ; compliance ; Delivery systems ; Drug Carriers - chemistry ; Drug Carriers - therapeutic use ; gastrointestinal system ; Humans ; lipids ; manufacturing ; nanocarriers ; Nanoparticles ; Nanostructures - chemistry ; Nanostructures - therapeutic use ; Oral delivery ; peptides ; Peptides - chemistry ; Peptides - therapeutic use ; polymers ; proteins ; Proteins - chemistry ; Proteins - therapeutic use</subject><ispartof>Peptides (New York, N.Y. : 1980), 2018-03, Vol.101, p.112-123</ispartof><rights>2018 Elsevier Inc.</rights><rights>Copyright © 2018 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-deeee5aa05eec8cb0bde53598cdc5173299ba4e21f487e81735afbdc122462a13</citedby><cites>FETCH-LOGICAL-c430t-deeee5aa05eec8cb0bde53598cdc5173299ba4e21f487e81735afbdc122462a13</cites><orcidid>0000-0001-7164-8005 ; 0000-0001-6596-1927 ; 0000-0001-5763-7553 ; 0000-0002-0760-3184 ; 0000-0003-3007-7263</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0196978118300020$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29329977$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Batista, Patrícia</creatorcontrib><creatorcontrib>Castro, Pedro M.</creatorcontrib><creatorcontrib>Madureira, Ana Raquel</creatorcontrib><creatorcontrib>Sarmento, Bruno</creatorcontrib><creatorcontrib>Pintado, Manuela</creatorcontrib><title>Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides</title><title>Peptides (New York, N.Y. : 1980)</title><addtitle>Peptides</addtitle><description>For buccal administration of proteins and peptides with therapeutic interest, formulations must be mucoadhesive and present one or more permeability enhancers as nanoparticles to cross the mucus layer (A) and permeate the epithelia (B) to finally reach the blood stream (C). A portion of carried proteins/peptides will be swallowed. Nanoparticles will protect the integrity of carried proteins and peptides while in contact with acidic pH and proteases secreted in the stomach (D), allowing the carried molecules to permeate the intestinal epithelia (E) to reach the bloodstream. [Display omitted] •Oral delivery of proteins and peptides with therapeutic interest can be achieved.•Buccal delivery of therapeutic proteins and peptides represents an attractive, unexplored type of delivery rout.•Nanoparticles represent useful tools to highly increase the effectiveness of proteins and peptides administered per os.•Size, zeta potential, mucoadhesion or physicochemical composition must be tailored according to carried protein/peptide.•Nanoparticle functionalization and/or inclusion of nanocarriers within mucoadhesive delivery systems can induce an overall increase of bioavailability of carried proteins and peptides. Bioactive proteins and peptides have been used with either prophylactic or therapeutic purposes, presenting inherent advantages as high specificity and biocompatibility. Nanocarriers play an important role in the stabilization of proteins and peptides, offering enhanced buccal permeation and protection while crossing the gastrointestinal tract. Moreover, preparation of nanoparticles as oral delivery systems for proteins/peptides may include tailored formulation along with functionalization aiming bioavailability enhancement of carried proteins or peptides. Oral delivery systems, namely buccal delivery systems, represent an interesting alternative route to parenteric delivery systems to carry proteins and peptides, resulting in higher comfort of administration and, therefore, compliance to treatment. This paper outlines an extensive overview of the existing publications on proteins/peptides oral nanocarriers delivery systems, with special focus on buccal route. Manufacturing aspects of most commonly used nanoparticles for oral delivery (e.g. polymeric nanoparticles using synthetic or natural polymers and lipid nanoparticles) advantages and limitations and potential applications of nanoparticles as proteins/peptides delivery systems will also be thoroughly addressed.</description><subject>Administration, Oral</subject><subject>Bioactive protein/peptides</subject><subject>bioavailability</subject><subject>biocompatibility</subject><subject>Buccal delivery</subject><subject>compliance</subject><subject>Delivery systems</subject><subject>Drug Carriers - chemistry</subject><subject>Drug Carriers - therapeutic use</subject><subject>gastrointestinal system</subject><subject>Humans</subject><subject>lipids</subject><subject>manufacturing</subject><subject>nanocarriers</subject><subject>Nanoparticles</subject><subject>Nanostructures - chemistry</subject><subject>Nanostructures - therapeutic use</subject><subject>Oral delivery</subject><subject>peptides</subject><subject>Peptides - chemistry</subject><subject>Peptides - therapeutic use</subject><subject>polymers</subject><subject>proteins</subject><subject>Proteins - chemistry</subject><subject>Proteins - therapeutic use</subject><issn>0196-9781</issn><issn>1873-5169</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU2PFCEQhonRuOPqX9hw8OCl24KGbrhpNn4lm5gYPRMaql0mPU0LzCT776WdHa_LBQqeqnqpl5AbBi0D1r_ftyuuJXjMLQemWmAtAH9GdkwNXSNZr5-THTDdN3pQ7Iq8ynkPAEJo9ZJccd1xrYdhR9wPdLgUGpYcft-XXA-03CM9ZqRxootdorMpBUyZTjH9e4vJztTjHE6YHjZqDNG6UkO6pliw1qJ28fSi8DV5Mdk545vH_Zr8-vzp5-3X5u77l2-3H-8aJzoojce6pLUgEZ1yI4weZSe1ct5JNmyKRyuQs0moAVW9kXYavWOci55b1l2Td-e6VcWfI-ZiDiE7nGe7YDxmw6EfuBScPY0yrbRUgoOoaH9GXYo5J5zMmsLBpgfDwGxemL25_NRsXhhgpnpRE28eexzHA_r_aZfhV-DtGUjO2tUkPIVcbG0OAmppYbgcYMM-nDGssztVJ0x2AReHPiR0xfgYnpLyFwLXqw4</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Batista, Patrícia</creator><creator>Castro, Pedro M.</creator><creator>Madureira, Ana Raquel</creator><creator>Sarmento, Bruno</creator><creator>Pintado, Manuela</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>RCLKO</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0001-7164-8005</orcidid><orcidid>https://orcid.org/0000-0001-6596-1927</orcidid><orcidid>https://orcid.org/0000-0001-5763-7553</orcidid><orcidid>https://orcid.org/0000-0002-0760-3184</orcidid><orcidid>https://orcid.org/0000-0003-3007-7263</orcidid></search><sort><creationdate>20180301</creationdate><title>Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides</title><author>Batista, Patrícia ; Castro, Pedro M. ; Madureira, Ana Raquel ; Sarmento, Bruno ; Pintado, Manuela</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-deeee5aa05eec8cb0bde53598cdc5173299ba4e21f487e81735afbdc122462a13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Bioactive protein/peptides</topic><topic>bioavailability</topic><topic>biocompatibility</topic><topic>Buccal delivery</topic><topic>compliance</topic><topic>Delivery systems</topic><topic>Drug Carriers - chemistry</topic><topic>Drug Carriers - therapeutic use</topic><topic>gastrointestinal system</topic><topic>Humans</topic><topic>lipids</topic><topic>manufacturing</topic><topic>nanocarriers</topic><topic>Nanoparticles</topic><topic>Nanostructures - chemistry</topic><topic>Nanostructures - therapeutic use</topic><topic>Oral delivery</topic><topic>peptides</topic><topic>Peptides - chemistry</topic><topic>Peptides - therapeutic use</topic><topic>polymers</topic><topic>proteins</topic><topic>Proteins - chemistry</topic><topic>Proteins - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Batista, Patrícia</creatorcontrib><creatorcontrib>Castro, Pedro M.</creatorcontrib><creatorcontrib>Madureira, Ana Raquel</creatorcontrib><creatorcontrib>Sarmento, Bruno</creatorcontrib><creatorcontrib>Pintado, Manuela</creatorcontrib><collection>RCAAP open access repository</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Peptides (New York, N.Y. : 1980)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Batista, Patrícia</au><au>Castro, Pedro M.</au><au>Madureira, Ana Raquel</au><au>Sarmento, Bruno</au><au>Pintado, Manuela</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides</atitle><jtitle>Peptides (New York, N.Y. : 1980)</jtitle><addtitle>Peptides</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>101</volume><spage>112</spage><epage>123</epage><pages>112-123</pages><issn>0196-9781</issn><eissn>1873-5169</eissn><abstract>For buccal administration of proteins and peptides with therapeutic interest, formulations must be mucoadhesive and present one or more permeability enhancers as nanoparticles to cross the mucus layer (A) and permeate the epithelia (B) to finally reach the blood stream (C). A portion of carried proteins/peptides will be swallowed. Nanoparticles will protect the integrity of carried proteins and peptides while in contact with acidic pH and proteases secreted in the stomach (D), allowing the carried molecules to permeate the intestinal epithelia (E) to reach the bloodstream. [Display omitted] •Oral delivery of proteins and peptides with therapeutic interest can be achieved.•Buccal delivery of therapeutic proteins and peptides represents an attractive, unexplored type of delivery rout.•Nanoparticles represent useful tools to highly increase the effectiveness of proteins and peptides administered per os.•Size, zeta potential, mucoadhesion or physicochemical composition must be tailored according to carried protein/peptide.•Nanoparticle functionalization and/or inclusion of nanocarriers within mucoadhesive delivery systems can induce an overall increase of bioavailability of carried proteins and peptides. Bioactive proteins and peptides have been used with either prophylactic or therapeutic purposes, presenting inherent advantages as high specificity and biocompatibility. Nanocarriers play an important role in the stabilization of proteins and peptides, offering enhanced buccal permeation and protection while crossing the gastrointestinal tract. Moreover, preparation of nanoparticles as oral delivery systems for proteins/peptides may include tailored formulation along with functionalization aiming bioavailability enhancement of carried proteins or peptides. Oral delivery systems, namely buccal delivery systems, represent an interesting alternative route to parenteric delivery systems to carry proteins and peptides, resulting in higher comfort of administration and, therefore, compliance to treatment. This paper outlines an extensive overview of the existing publications on proteins/peptides oral nanocarriers delivery systems, with special focus on buccal route. Manufacturing aspects of most commonly used nanoparticles for oral delivery (e.g. polymeric nanoparticles using synthetic or natural polymers and lipid nanoparticles) advantages and limitations and potential applications of nanoparticles as proteins/peptides delivery systems will also be thoroughly addressed.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>29329977</pmid><doi>10.1016/j.peptides.2018.01.002</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-7164-8005</orcidid><orcidid>https://orcid.org/0000-0001-6596-1927</orcidid><orcidid>https://orcid.org/0000-0001-5763-7553</orcidid><orcidid>https://orcid.org/0000-0002-0760-3184</orcidid><orcidid>https://orcid.org/0000-0003-3007-7263</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0196-9781
ispartof Peptides (New York, N.Y. : 1980), 2018-03, Vol.101, p.112-123
issn 0196-9781
1873-5169
language eng
recordid cdi_proquest_miscellaneous_2067254211
source MEDLINE; Elsevier ScienceDirect Journals
subjects Administration, Oral
Bioactive protein/peptides
bioavailability
biocompatibility
Buccal delivery
compliance
Delivery systems
Drug Carriers - chemistry
Drug Carriers - therapeutic use
gastrointestinal system
Humans
lipids
manufacturing
nanocarriers
Nanoparticles
Nanostructures - chemistry
Nanostructures - therapeutic use
Oral delivery
peptides
Peptides - chemistry
Peptides - therapeutic use
polymers
proteins
Proteins - chemistry
Proteins - therapeutic use
title Recent insights in the use of nanocarriers for the oral delivery of bioactive proteins and peptides
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T19%3A42%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20insights%20in%20the%20use%20of%20nanocarriers%20for%20the%20oral%20delivery%20of%20bioactive%20proteins%20and%20peptides&rft.jtitle=Peptides%20(New%20York,%20N.Y.%20:%201980)&rft.au=Batista,%20Patr%C3%ADcia&rft.date=2018-03-01&rft.volume=101&rft.spage=112&rft.epage=123&rft.pages=112-123&rft.issn=0196-9781&rft.eissn=1873-5169&rft_id=info:doi/10.1016/j.peptides.2018.01.002&rft_dat=%3Cproquest_cross%3E2067254211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1989584204&rft_id=info:pmid/29329977&rft_els_id=S0196978118300020&rfr_iscdi=true